Today's Daily Dose brings you news about Bio-Techne's first acquisition for the year; Tetraphase's submission of NDA for IV Eravacycline; Five prime's progress in phase I/III clinical trial of FPA144, and FDA's acceptance of Trevena's OLINVO NDA for review, to name a few.
from RTT - Biotech http://ift.tt/2qf4mtn
via IFTTT
No comments:
Post a Comment